Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SQZ-eAPC-HPV |
Synonyms | |
Therapy Description |
SQZ-eAPC-HPV are antigen-presenting cells engineered with mRNAs encoding HPV16 E6 and E7 antigens, CD86, and membrane bound IL-2 and IL-12, which may lead to a a cytotoxic T-lymphocyte (CTL)-mediated response against HPV16 E6/E7-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2022;10; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SQZ-eAPC-HPV | SQZ-eAPC-HPV are antigen-presenting cells engineered with mRNAs encoding HPV16 E6 and E7 antigens, CD86, and membrane bound IL-2 and IL-12, which may lead to a a cytotoxic T-lymphocyte (CTL)-mediated response against HPV16 E6/E7-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2022;10; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05357898 | Phase Ib/II | SQZ-eAPC-HPV Pembrolizumab + SQZ-eAPC-HPV | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |